cyflow cube8 robby flow cytometer (Sysmex Corporation)
86
Structured Review
Sysmex Corporation
cyflow cube8 robby flow cytometer
Cyflow Cube8 Robby Flow Cytometer, supplied by Sysmex Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cyflow+cube8+robby+flow+cytometer/cyflow+cytometer+flow+space/pm38705254-70-10-15
Average 86 stars, based on 1 article reviews
Cyflow Cube8 Robby Flow Cytometer, supplied by Sysmex Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cyflow+cube8+robby+flow+cytometer/cyflow+cytometer+flow+space/pm38705254-70-10-15
Average 86 stars, based on 1 article reviews
cyflow cube8 robby flow cytometer - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
Flow Cytometry:Article Title: Endothelial dysfunction and complement activation are independently associated with disease duration in patients with systemic vasculitis. Article Snippet: Objectives: Systemic vasculitis is a heterogenous group of autoimmune diseases characterized by enhanced cardiovascular mortality.. Endothelial dysfunction is associated with accelerated vascular damage, representing a core pathophysiologic mechanism contributing to excess CV risk.. Recent studies have also shown that complement activation holds significant role in the pathogenesis of Anti-Neutrophilic Cytoplasmic Autoantibody (ANCA) -associated vasculitis (AAV). Article Title: Patients with autoimmune chronic inflammatory diseases present increased biomarkers of thromboinflammation and endothelial dysfunction in the absence of flares and cardiovascular comorbidities. Article Snippet: Cardiovascular risk is increased in patients with autoimmune rheumatic diseases.. Endothelial, erythrocyte and platelet microvesicles (MVs) are elevated in patients with cardiovascular diseases and represent novel markers of endothelial dysfunction and thromboinflammation.. We tested whether their levels are increased in patients with autoimmune rheumatic diseases (ARDs) in the absence of disease flare and cardiovascular comorbidities. |